HIGHLIGHTS
- who: Marcela Freitas et al. from the Department of Biochemical and Pharmaceutical Technology, University of Sao Paulo have published the research work: L-Asparaginase from Penicillium sizovae Produced by a Recombinant Komagataella phaffii Strain, in the Journal: Pharmaceuticals 2022, 746 of 27/01/2019
- what: As the main reason for the interruption of L-asparaginase treatment is the development of hypersensitivity, caused partly by the protein`s high molecular weight and bacterial origin, an enzyme that leads to fewer side effects could be found in other microbial sources such as fungi, which are eukaryotic microorganisms . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.